Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey Silver who wrote (355)	11/15/1998 11:59:00 PM
From: Charles Holewinski	Read Replies (1) \| Respond to of 410

Hi Jeffrey, Thanks for your reply. It answers why the GENZ does the spin offs; but I still do not think it is of any benefit to the holders of GENZ, who wind up with a bunch of an odd number of shares of various stocks. It seems to me that these spun off shares will only go down in value as time passes because the drug or therapy they represent will eventually decline in use when better drugs are developed or the patent expires and a cheaper generic is developed. If the spun off shares paid a dividend equal to the profits of the drug they represent at least the holders would be receiving a reward for holding the shares; but once the shares are issued and the full potential of the drug is reached, it seems to me the shares will eventually become worthless and the holders will not have received any reward for holding on to them. Granted the drugs or therapies will not be totally devalued overnight but they certainly do not represent a growth situation. Do you see any benefit in holding the spun off shares? Would like your opinion as to my thoughts. If I am missing something I would like to know. Charlie